1
|
Mineur L, François E, Plassot C, Phelip JM, Miglianico L, Dourthe LM, Bonichon N, Moreau L, Guimbaud R, Smith D, Achille E, Hervé R, Bons JM, Remy S, Faroux R, Villing AL, Mahamat A, Rabbia I, Soulié P, Baumgaertner I, Mathé N, Vazquez L, Boustany R. PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer. PLoS One 2020; 15:e0243997. [PMID: 33347495 PMCID: PMC7752147 DOI: 10.1371/journal.pone.0243997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Accepted: 12/01/2020] [Indexed: 11/18/2022] Open
Abstract
Background Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab treatment, which is, in combination with chemotherapy, a standard-of-care first-line treatment regimen for patients with KRAS wt mCRC. Patients and methods PREMIUM is a prospective, French multicenter, observational study that recruited patients with KRAS wt mCRC scheduled to receive cetuximab, with or without first-line chemotherapy, as part of routine clinical practice, between October 28, 2009 and April 5, 2012 (ClinicalTrials.gov Identifier: NCT01756625). The main endpoints were the factors impacting on efficacy and compliance to cetuximab treatment. Predefined efficacy endpoints were PFS and safety. Results A total of 493 patients were recruited by 94 physicians. Median follow-up was 12.9 months. Median progression-free survival was 11 months [9.6–12]. In univariate analyses, ECOG performance status (PS), smoking status, primary tumor location, number of metastatic organs, metastasis resectability, surgery, folliculitis, xerosis and paronychia maximum grade, and acne preventive treatment were statistically significant. In multivariate analysis (Hazard Ratios of multivariate stepwise Cox models), ECOG PS, surgery, xerosis and folliculitis were positive prognostics factors for longer PFS. Among all patients, 69 (14%) were non-compliant. In multivariate analysis, no variables were statistically significant. The safety profile of cetuximab was consistent with previous studies. Conclusions ECOG PS <2, surgical treatment performed, and maximum grade xerosis or folliculitis developed were predictive factors of cetuximab efficacy on KRAS wt mCRC patients. Unfortunately, we failed in identifying predictive factors for compliance in these patients.
Collapse
Affiliation(s)
- L. Mineur
- Institut Sainte-Catherine, Avignon, France
| | | | - C. Plassot
- Institut Universitaire de Recherche Clinique, Montpellier, France
| | - J. M. Phelip
- Hopital universitaire CHU Nord Saint Etienne, Saint Etienne, France
| | | | | | | | - L. Moreau
- Clinique les Domes, Clermont-Ferrand, France
| | | | - D. Smith
- Hopital Saint-André, Bordeaux, France
| | - E. Achille
- Clinique de l’Orangerie, Strasbourg, France
| | - R. Hervé
- CH Privé Clairval, Marseille, France
| | - J. M. Bons
- Polyclinique Saint-Francois, Desertine, France
| | - S. Remy
- Centre d’Oncologie de la côte Basque, Bayonne, France
| | | | | | | | - I. Rabbia
- Cabinet médical, Orange, Paris, France
| | | | | | - N. Mathé
- Centre Clinique de Soyaux, Soyaux, France
| | - L. Vazquez
- Institut Sainte-Catherine, Avignon, France
- * E-mail:
| | | |
Collapse
|
2
|
Vincent L, Ceballos P, Plassot C, Méniane JC, Quittet P, Navarro R, Cyteval C, Szablewski V, Lu ZY, Kanouni T, Moreaux J, Cartron G, Klein B, Fegueux N. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Blood Cancer J 2015; 5:e341. [PMID: 26295611 PMCID: PMC4558584 DOI: 10.1038/bcj.2015.48] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Affiliation(s)
- L Vincent
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France.,Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France
| | - P Ceballos
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - C Plassot
- Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France
| | - J C Méniane
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - P Quittet
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - R Navarro
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - C Cyteval
- Département d'Imagerie Médicale CHRU de Montpellier, Montpellier, France
| | - V Szablewski
- Département d'Anatomopathologie, CHRU de Montpellier, Montpellier, France
| | - Z Y Lu
- Unité de Thérapie Cellulaire, CHRU de Montpellier, Montpellier, France
| | - T Kanouni
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - J Moreaux
- INSERM, U1040, Montpellier, France.,Laboratory for Innovative Biology, Department of Biological Hematology, CHRU de Montpellier, Montpellier, France
| | - G Cartron
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France.,Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France
| | - B Klein
- Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France.,INSERM, U1040, Montpellier, France.,Laboratory for Innovative Biology, Department of Biological Hematology, CHRU de Montpellier, Montpellier, France
| | - N Fegueux
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| |
Collapse
|
3
|
Corre R, Chouaid C, Greillier L, Caer HL, Valette CA, Baize N, Berard H, Falchero L, Descourt R, Dansin E, Vergnenegre A, Bigay-Gamé L, Schott R, Garff GL, Treut JL, Sureda BM, Daures J, Plassot C, Lena H. Quality of Life Analysis of Esogia-Gfpc-Gecp Trial- a Phase Iii, Randomized, Multicenter Study Comparing in Elderly Patients (≥70 Years) with Stage Iv Nsclc a Treatment Allocation Based on Ps and Age with an Experimental Strategy According to a Comprehensive Geriatric Assessment (Cga). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|